Peripheral blood-derived mononuclear cells (PBMCs) are purified from an apheresis leukopak product which contains a highly enriched population of mononuclear cells when compared to buffy coat or whole blood.
COVID-19 vaccinated PBMCs are isolated from a leukopak collected from consented healthy donors with no prior COVID-19 infection who have received a COVID-19 vaccine from Pfizer, Moderna, or Johnson & Johnson (J&J). The COVID-19 vaccinated PBMCs (time series) are collected at the following time points:
- prior to COVID-19 vaccination
- 10-30 days after the first vaccine administration
- 10-30 days after the second vaccine administration (when applicable)
The COVID-19 vaccinated PBMCs are purified by density gradient centrifugation and are available in cryopreserved format.
COVID-19 vaccinated PBMCs can be used as a unique research tool to investigate the immune response within our body to understand the deadly pathology of COVID-19 and to examine vaccine efficacy between different population subgroups.
Prepare PBMCs for long-term storage in liquid nitrogen vapor phase or thaw for use. Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately.
Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1.